«È un momento cruciale per migliorare il nostro approccio alle cure», afferma Dennis Slamon, oncologo attivo sul tema, in ...
In arrivo numerose assunzioni Novartis in Campania. La casa farmaceutica amplierà lo stabilimento di Torre Annunziata (Napoli ...
In this article, we are going to take a look at where Novartis AG (NYSE:NVS) stands against the other stocks on Jim Cramer’s radar. Jim Cramer often reflects on how he would reform the American ...
Novartis AG (NYSE:NVS) is a Swiss multinational pharmaceutical company that specializes in innovative drugs across key areas like oncology, rare diseases, neuroscience, and cardio-metabolic ...
Nuovi batteri nelle acque del Mar Glaciale Artico potrebbero essere la chiave per contrastare gli agenti patogeni che resistono agli attuali antibiotici e permettere così l’accesso a cure ...
Novartis’ blood cancer sculpture tour has reached a new destination. The Swiss drugmaker, which put the sculptures on show in London one year ago, is marking this year’s Blood Cancer Awareness ...
Lindy Biosciences has announced an exclusive global licensing agreement and strategic collaboration with Novartis Pharma AG. The deal centres on Lindy’s microglassification technology, which ...
Natco Pharma has submitted to the U.S. Food and Drug Administration an abbreviated new drug application for a generic version of Novartis’ cancer drug Tabrecta (capmatinib hydrochloride).
The trial compared the efficacy of Novartis’ Leqvio as a single agent against ezetimibe and a placebo. Credit: VILTVART/Shutterstock. Novartis has revealed that its Phase III V-MONO clinical trial of ...
Novartis has formed a strategic collaboration with drug delivery specialist Lindy Biosciences to develop self-administered versions of the Swiss pharma’s innovative drugs. For $20 million ...
Novartis and other drugmakers have invested in radiopharmaceuticals to treat cancer. The programs require a supply of radioactive compounds that must be produced close to patients because they have ...
No­var­tis is sell­ing off its mol­e­c­u­lar imag­ing busi­ness for positron emis­sion to­mog­ra­phy (PET) scans to Siemens Health­i­neers for an undis­closed amount, both com­pa ...